Polycystic ovary syndrome is characterized by insulin resistance, anovulation, and metabolic dysfunction — pathophysiology that aligns mechanistically with GLP-1 RA therapy. Evidence for weight loss is strong; evidence for cycle regularity and ovulation is emerging.
The evidence
GLP-1 RA evidence in PCOS: observational and small RCT data show weight loss, improved insulin sensitivity, reduced androgen levels, improved menstrual regularity. Larger phase 3 trials specific to PCOS are limited.
FDA-approved labeling status
No GLP-1 RA has a PCOS-specific FDA indication. Use in PCOS is off-label, typically through the obesity indication if BMI eligibility is met.
Practical considerations
Critical fertility consideration: GLP-1 RAs may restore ovulation in patients with weight-related anovulation. Unexpected pregnancy is well-documented. Effective contraception is essential during therapy. Tirzepatide specifically has documented oral-contraceptive interaction — backup contraception recommended for 4 weeks at initiation and after each dose escalation. Wash-out before planned conception.
See also
GLP-1 for PCOS patients · Drug interactions (oral contraceptives)